By: Nic Abelian
As life sciences firms navigate complex operational landscapes, they are reportedly grappling with approximately $2.3B in annual inefficiencies caused by disjointed customer experience tools (according to Accenture). In response, a startup led by industry veterans is developing AI-powered applications intended to streamline workflows and offer new ways to explore analytical insights. The article examines whether the shift toward proactive platforms can offer significant benefits while also meeting strict data compliance requirements.
The traditional consulting model in life sciences has long relied on static dashboards and one-off project engagements. This legacy approach has contributed to a fragmented system in which a significant percentage of pharma leaders—68%, according to McKinsey—report gaps in customer experience, particularly in field reporting. Such fragmentation can contribute to slower drug launches, increased operational costs, and reduced responsiveness to changing market needs. Companies across the sector are seeking more integrated, adaptable solutions—a demand that Improzo, a life sciences technology startup, is working to meet.
Improzo introduces an approach centered on a transparent and interoperable suite of AI applications, designed to support life sciences organizations in their digital transformation efforts. These tools, described by the company as “Agentic Applications,” are built to continuously adapt and generate context-aware recommendations without requiring teams to overhaul existing systems. According to the company, the tools can be integrated with or detached from existing tech and analytics stacks, potentially offering flexibility for organizations looking to innovate incrementally. This aligns with industry-wide movements toward connected, self-service systems and modular interoperability, as noted in Deloitte’s 2024 Life Sciences Tech Survey.
The startup’s founding team, with a combined 70+ years of experience at consulting and analytics providers, envisioned a platform where more accessible data could facilitate quicker, more informed decision-making. One of the co-founders explained, “Life sciences firms need simple tools that help them operate more efficiently. Our focus is on creating applications that support performance improvement by simplifying core processes.” Rather than making broad promises, the company emphasizes building tools grounded in real operational challenges.
Where many service providers rely on generalized platforms, Improzo offers a purpose-built application layer developed specifically for the life sciences sector. This approach allows them to leverage deep industry knowledge to build systems that address real-world needs, whether in commercial engagement, field reporting, or customer retention. The platform’s adaptability also allows it to evolve alongside business needs—critical in a digital landscape that is both highly regulated and rapidly changing. By analyzing data such as usage logs, the platform is designed to refine its analytics over time, potentially improving accuracy in a way that responds to actual user interaction.
Improzo’s application layer may reflect a growing shift in how life sciences companies think about operational agility. Already being used by a subset of the 20 pharma firms the company engages with, the platform is positioned to reduce the industry’s reliance on expensive, project-based consulting models and siloed analytics tools. By centralizing relevant data, automating routine reporting tasks, and offering self-service business intelligence features, Improzo aims to help internal teams operate more strategically and independently.
In addition, the system incorporates data governance protocols and built-in security features, making sure that only authorized personnel can access sensitive information. This approach may enable teams to retain greater control over data, while continuing to meet privacy and compliance standards. According to the company, this framework supports internal ownership of both data and insights without exposing organizations to undue risk.
The movement toward modular, AI-enabled platforms such as those offered by Improzo is about more than digitizing legacy tools—it represents a gradual rethinking of how life sciences companies approach customer experience and internal decision-making. By addressing a well-recognized problem with a tailored, flexible framework, the company appears to be carving out a space within a highly specialized industry ecosystem.
Looking ahead, Improzo is focusing on expanding its library of applications and developing new collaboration features intended to connect commercial, medical, and data teams in more dynamic ways. While results will depend on how each organization implements the tools, the startup remains focused on maintaining transparency and user control. Clients can choose individual apps, monitor performance, and adjust usage as needs evolve—offering a level of operational choice that may appeal to teams working within strict regulatory environments.
Ultimately, Improzo presents a case study in how targeted, experience-driven solutions may evolve the digital experience within the life sciences industry. While no single platform can solve all industry challenges, the company’s modular and interoperable approach reflects a wider shift toward more nimble, user-driven technologies that prioritize configurability and compliance.
For organizations balancing complexity, cost control, and rapid market shifts, Improzo’s tools offer a framework that could support more informed and timely decisions—without compromising on privacy, data control, or system compatibility.
To learn more, visit www.improzo.com.
Connect with Abhishek Trigunait, CTO of Improzo, on LinkedIn: Abhishek Trigunait
Published by Jeremy S.
